U=U is our good news strategy to end HIV as a public health threat – simply communicating this news has profound individual and population-level impacts
In Conversation
As multinational companies, we must not only localize our operations but also recognize and leverage the unique strengths and perspectives of our Chinese counterparts
True biotech isn't about managing portfolios like big pharma does. It's about addressing unmet medical needs where there's a clinical void that larger pharmaceutical companies haven't…
The transition to annual updates [of China's National Reimbursement Drug List] has greatly enhanced patient access to innovative drugs, reflecting positive changes in the regulatory landscape
The 2030 goals are not the last mile, and the lack of political will to work towards achieving them is a big concern
The drug discovery industry is moving into a different, technology- and engineering-driven, phase. This favours China, which is very good at engineering and assembling novel molecules…
Rather than dwelling on the challenges, I urge everyone to engage, be pro-active, and become part of the solution. This is a unique moment in Saudi's…
What gives me hope is the incredible progress in the scientific tools at our disposal and our understanding of what we are after
Transforming our affiliate into a talent powerhouse and fostering innovation aligns with our commitment to addressing healthcare challenges and making a lasting impact in Saudi Arabia
By maintaining a collaborative approach and focusing on key objectives, I’m confident that we can achieve even greater things for rare disease patients in 2024 and…
GSK is actively collaborating with the [Saudi] government to enhance awareness and knowledge surrounding adult vaccinations, recognizing the importance of lifelong immunization
Both the public and private sectors are instrumental in driving healthcare transformation in Saudi Arabia
